Doctorsa raises US$1.09M (€1M) to expand global telemedicine platform for travellers
DoctorsaCompany
PranaVenturesInvestor
VentoInvestor
40 Jemz VenturesInvestor
Doctorsa, the Milan‑based telemedicine platform for travelers, raised US$1.09 million (€1 million) on July 13, 2026, led by PranaVentures with participation from Vento and 40Jemz Ventures, to fund U.S. expansion and a new B2B offering for travel‑related partners.
Doctorsa has raised US$1.09 million (€1 million) to expand its global telemedicine platform for travelers, with PranaVentures leading the round and Vento and 40Jemz Ventures participating. The funding, announced on July 13, 2026, will be deployed to accelerate entry into the United States and to launch a B2B product suite aimed at travel operators, insurers and employers.
Deal Terms
The round was an undisclosed‑type venture funding transaction; no valuation or revenue multiples were disclosed. The capital comes from PranaVentures' first fund, supplemented by strategic capital from Vento and 40Jemz Ventures. Doctorsa will use the proceeds to deepen its presence in existing markets, scale its proprietary Agentic Booking AI infrastructure, and hire sales and engineering talent to support the upcoming B2B go‑to‑market plan.
Strategic Rationale
Travel‑related health services have surged as international mobility rebounds, and Doctorsa’s model—pay‑per‑consultation with 5‑minute matching across 550 doctors in 40 countries—addresses a clear gap in urgent‑care coverage for itinerant consumers. The company’s AI‑driven booking layer lets users request appointments through any digital assistant, a capability that aligns with the broader shift toward agentic commerce in travel. By adding a B2B layer, Doctorsa can embed its service into the customer experience of airlines, OTA platforms, and corporate travel programs, turning a consumer‑facing product into a recurring revenue engine with higher net‑revenue retention potential.
The U.S. market, where roughly 40 % of Doctorsa’s patients already reside, offers a sizable addressable base and a mature insurance ecosystem that can accelerate adoption of the B2B solution. PranaVentures highlighted the “vertical with significant opportunities for innovation and long‑term value creation,” underscoring the strategic fit between the investor’s health‑tech focus and Doctorsa’s cross‑border telemedicine proposition.
Overall, the raise positions Doctorsa to transition from a niche consumer service to a platform‑as‑a‑service (PaaS) provider for travel‑related stakeholders, leveraging AI to lock in repeat usage and expand its revenue mix beyond per‑consultation fees.
Why It Matters
For Doctorsa, the new capital unlocks a faster rollout of its B2B offering, which could shift the company’s revenue profile from low‑margin, transaction‑based fees to higher‑margin subscription or usage‑based contracts with travel partners. Competitors that rely solely on direct‑to‑consumer models may see pressure to add enterprise integrations or risk losing market share in the high‑value corporate travel segment.
Travel operators and insurers gain a ready‑made telemedicine layer that can be white‑labeled, reducing the time and cost to embed health services into their own platforms. This could accelerate consolidation among travel‑tech providers that are looking to differentiate through health‑centric experiences, potentially prompting further M&A activity in the travel‑health niche.
Key Points
- Doctorsa raised US$1.09 million (€1 million) in a venture round led by PranaVentures.
- Vento and 40Jemz Ventures participated in the financing.
- The funds will support U.S. market expansion and a new B2B offering for travel‑related partners.
- Doctorsa’s platform connects travelers with 550 doctors across 40 countries via a 5‑minute matching system.
- The company is deploying an AI‑driven Agentic Booking infrastructure to enable bookings through digital assistants.
Analysis
The €1 million raise, while modest in absolute terms, signals growing investor appetite for niche vertical SaaS solutions that combine AI and telehealth. Although no ARR or valuation multiple was disclosed, the capital infusion suggests Doctorsa is still in an early‑stage growth phase where scaling distribution and productizing the platform for enterprise clients are higher priorities than profitability metrics. The move aligns with a broader trend of health‑tech firms targeting the travel vertical, a segment that benefits from high‑frequency, low‑ticket‑size transactions and strong cross‑border demand. By embedding its service into travel operators and insurers, Doctorsa can capture higher net‑revenue retention through multi‑year contracts, improve gross margins via economies of scale, and create defensible data assets that enhance its AI matchmaking engine. For investors, the deal illustrates the potential upside of backing platforms that address fragmented consumer pain points with a B2B‑enabled SaaS model, especially as travel volumes rebound and corporate wellness budgets expand. The funding also underscores the importance of operational support from investors like PranaVentures, who bring sector expertise that can accelerate go‑to‑market execution and open strategic partnership pipelines.